JP2018528263A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528263A5
JP2018528263A5 JP2018527025A JP2018527025A JP2018528263A5 JP 2018528263 A5 JP2018528263 A5 JP 2018528263A5 JP 2018527025 A JP2018527025 A JP 2018527025A JP 2018527025 A JP2018527025 A JP 2018527025A JP 2018528263 A5 JP2018528263 A5 JP 2018528263A5
Authority
JP
Japan
Prior art keywords
composition
compound
subject
need
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018527025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528263A (ja
JP7054674B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/001244 external-priority patent/WO2017025802A1/en
Publication of JP2018528263A publication Critical patent/JP2018528263A/ja
Publication of JP2018528263A5 publication Critical patent/JP2018528263A5/ja
Priority to JP2021181238A priority Critical patent/JP2022023215A/ja
Application granted granted Critical
Publication of JP7054674B2 publication Critical patent/JP7054674B2/ja
Priority to JP2024010113A priority patent/JP2024050701A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018527025A 2015-08-11 2016-08-11 Dpep-1結合組成物および使用の方法 Active JP7054674B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021181238A JP2022023215A (ja) 2015-08-11 2021-11-05 Dpep-1結合組成物および使用の方法
JP2024010113A JP2024050701A (ja) 2015-08-11 2024-01-26 Dpep-1結合組成物および使用の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562203704P 2015-08-11 2015-08-11
US62/203,704 2015-08-11
US201562264032P 2015-12-07 2015-12-07
US62/264,032 2015-12-07
PCT/IB2016/001244 WO2017025802A1 (en) 2015-08-11 2016-08-11 Dpep-1 binding compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021181238A Division JP2022023215A (ja) 2015-08-11 2021-11-05 Dpep-1結合組成物および使用の方法

Publications (3)

Publication Number Publication Date
JP2018528263A JP2018528263A (ja) 2018-09-27
JP2018528263A5 true JP2018528263A5 (cg-RX-API-DMAC7.html) 2019-09-19
JP7054674B2 JP7054674B2 (ja) 2022-04-14

Family

ID=57983413

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018527025A Active JP7054674B2 (ja) 2015-08-11 2016-08-11 Dpep-1結合組成物および使用の方法
JP2021181238A Pending JP2022023215A (ja) 2015-08-11 2021-11-05 Dpep-1結合組成物および使用の方法
JP2024010113A Pending JP2024050701A (ja) 2015-08-11 2024-01-26 Dpep-1結合組成物および使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021181238A Pending JP2022023215A (ja) 2015-08-11 2021-11-05 Dpep-1結合組成物および使用の方法
JP2024010113A Pending JP2024050701A (ja) 2015-08-11 2024-01-26 Dpep-1結合組成物および使用の方法

Country Status (8)

Country Link
US (3) US10493127B2 (cg-RX-API-DMAC7.html)
EP (2) EP3334459B1 (cg-RX-API-DMAC7.html)
JP (3) JP7054674B2 (cg-RX-API-DMAC7.html)
AU (3) AU2016305299B2 (cg-RX-API-DMAC7.html)
CA (2) CA2999800C (cg-RX-API-DMAC7.html)
ES (1) ES3057215T3 (cg-RX-API-DMAC7.html)
IL (2) IL257458B2 (cg-RX-API-DMAC7.html)
WO (1) WO2017025802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334459B1 (en) * 2015-08-11 2025-12-17 Arch Biopartners, Inc. Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
AU2017281744B2 (en) * 2016-06-24 2022-10-27 Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón Cilastatin for use in the treatment of sepsis
US11286278B2 (en) * 2018-11-30 2022-03-29 Arch Biopartners, Inc. DPEP-1 binding agents and methods of use
KR102730193B1 (ko) * 2020-07-24 2024-11-14 신규철 단일성분의 마이크로구조체 색전물질과 그 색전물질을 이용한 색전술로 시행되는 치료방법
KR102486996B1 (ko) * 2020-09-04 2023-01-10 서울대학교병원 펩타이드 및 이를 포함하는 피부 주름 개선용 조성물 및 대사성 질환 치료용 조성물
CA3214739A1 (en) * 2021-04-08 2022-10-13 Jamshid Tanha Dpep-1 binding agents and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5629179A (en) 1995-03-17 1997-05-13 Novagen, Inc. Method and kit for making CDNA library
US5698401A (en) 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
US6174687B1 (en) 1999-02-26 2001-01-16 The Burnham Institute Methods of identifying lung homing molecules using membrane dipeptidase
ATE407943T1 (de) * 1998-03-13 2008-09-15 Burnham Inst Zielsuchende verbindungen für verschiedene organe und gewebe
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US6927212B2 (en) 2002-07-27 2005-08-09 The Johns Hopkins University Design and synthesis of renal dipeptidase inhibitors
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2006010496A1 (en) * 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidase 1 (dpep1)
EP3461499A1 (en) 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
US20100324469A1 (en) 2007-10-04 2010-12-23 Josai University Corporation Drug product, a method of administrating a vaccine using the drug product, and an apparatus for iontophoresis
WO2010004060A1 (es) * 2008-07-11 2010-01-14 Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Marañon Uso de la cilastatina para reducir la nefrotoxicidad de distintos compuestos
US20120210458A9 (en) 2009-02-27 2012-08-16 Yongwei Cao Isolated Novel Nucleic Acid and Protein Molecules from Corn and Methods of Using Thereof
US20130203726A1 (en) * 2010-03-09 2013-08-08 Terry Roemer FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
AU2015218198B2 (en) * 2014-02-13 2019-07-11 Arch Cancer Therapeutics, Inc. Peptides that block leukocyte recruitment and methods of use
EP3334459B1 (en) * 2015-08-11 2025-12-17 Arch Biopartners, Inc. Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
AU2017281744B2 (en) 2016-06-24 2022-10-27 Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón Cilastatin for use in the treatment of sepsis

Similar Documents

Publication Publication Date Title
Saliba et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial
Garcia-Sanz et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Petruzziello-Pellegrini et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin–associated hemolytic uremic syndrome in humans and mice
JP7445893B2 (ja) ヒトにおける固形腫瘍の処置のためのC.novyi
Zeller et al. A novel phosphocholine‐mimetic inhibits a pro‐inflammatory conformational change in C‐reactive protein
CN104717966B (zh) 用于癌症靶向治疗和预防癌症复发的含有基于血红蛋白的氧载体的药物组合物
Berger et al. Update on C1 esterase inhibitor in human solid organ transplantation
CA3025442C (en) Cpf-373 protide for use in treating cancer
JP2018516944A5 (cg-RX-API-DMAC7.html)
JP2019519533A5 (cg-RX-API-DMAC7.html)
Yadav et al. Remediation of hemorrhagic shock-induced intestinal barrier dysfunction by treatment with diphenyldihaloketones EF24 and CLEFMA
JP2016537380A5 (cg-RX-API-DMAC7.html)
EP4568663A1 (en) Compositions for and methods of precision cancer treatment
Kuo et al. Molecular mechanisms of chronic rejection following transplantation
WO2022149605A1 (ja) 重症肺高血圧症、治療抵抗性肺高血圧症、又は薬剤性肺高血圧症の予防又は治療薬
Roh et al. Identification and characterization of warm temperature acclimation proteins (Wap65s) in rainbow trout (Oncorhynchus mykiss)
JP2017508734A5 (cg-RX-API-DMAC7.html)
Wen et al. HLA-DR overexpression in tubules of renal allografts during early and late renal allograft injuries
Sihag et al. Natural IgM blockade limits infarct expansion and left ventricular dysfunction in a swine myocardial infarct model
JP2018500879A5 (cg-RX-API-DMAC7.html)
JPWO2021066062A5 (cg-RX-API-DMAC7.html)
EP3952868A1 (en) Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
Kostyak et al. Plk3 Regulates Bacteremia and Supports Sepsis
JP7045047B2 (ja) 腫瘍溶解性ウイルスの抗腫瘍効果増強剤
Ferreira Alves New pharmacological strategies to counteract the major inflammatory triggers of organ injury in cardiovascular diseases